AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 40 filers reported holding AXOVANT GENE THERAPIES LTD in Q2 2019. The put-call ratio across all filers is 0.99 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $115,000 | – | 18,400 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 1,021,566 | $2,493,000 | 1.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 2,931,018 | $7,152,000 | 0.90% |
| Consonance Capital Management LP | 3,653,303 | $8,914,000 | 0.66% |
| Rubric Capital Management LP | 460,200 | $1,123,000 | 0.18% |
| Hudson Bay Capital Management LP | 1,350,000 | $3,294,000 | 0.08% |
| Ikarian Capital, LLC | 188,884 | $461,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 41,037 | $100,000 | 0.02% |
| Spark Investment Management LLC | 18,072 | $44,000 | 0.02% |
| Cable Hill Partners, LLC | 15,000 | $37,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 38,800 | $95,000 | 0.01% |